Comparing Rezdiffra with Wegovy and Mounjaro In the context of NAFLD/NASH (MASLD/MASH)

Understanding how these very different drugs work in the context of steatotic liver disease

At the end of 2024 there are three drugs available for patients dealing with obesity and its consequences for liver disease.  Resmetirom marketed as Rezdiffra (Madrigal) is a liver specific drug and Semaglutide marketed as Wegovy (Novo Nordisk) and Tirzepatide marketed as Mounjaro by (Eli Lilly) are both focused on weight loss outside the liver. 

Resmetirom, developed by Madrigal Pharmaceuticals is for the treatment of nonalcoholic steatohepatitis (NASH). Resmetirom is a selective thyroid hormone receptor beta (THR-β) agonist, and its mechanism of action is distinct from both Semaglutide and Tirzepatide. Both of those drugs are GLP-1 agonists directed at weight loss and type 2 diabetes through reduction of obesity. A comparison of their mechanisms and actions in table form but a more expansive report is available by clicking on the table.

Day to day living can be challenging when dealing with a disease.  Many people don't know what services are available to them in their local area. Finding those local resources in their local zip code is often a challenge for patients. We are developing a tool to help with that. Would you take a few minutes and examine our tool for locating local services?  Just click on the link below: enter your local zip-code in the form: explore how the services available to you in your area are shown: and take the short survey. The elements above the zip code function are under development, so don't comment on those just yet.

The Wellness League Local Search Tool

I will really appreciate it if you take this few minutes to give us feedback. As patients ourselves, how to live in the best way possible while dealing with illness is important. Your opinion matters.